Relay Therapeutics to Announce Third Quarter 2026 Financial Results and Corporate Highlights on November 4, 2026

CAMBRIDGE, Mass., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, will report third quarter 2026 financial results and corporate highlights after the U.S. financial markets close on Wednesday, November 4, 2026.

GlobeNewsWire • Oct 28, 2026

Large biopharma companies looking at China assets right now, says Goldman Sachs Salveen Richter

Salveen Richter, Goldman Sachs lead U.S. biotech analyst, joins 'Closing Bell Overtime' to talk biotech innovations in China.

CNBC Television • Oct 6, 2026

Relay Therapeutics, Inc. (RLAY) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Relay Therapeutics, Inc. (RLAY) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Seeking Alpha • Sep 16, 2026

Relay Therapeutics, Inc. (RLAY) Presents at Wells Fargo 21st Annual Healthcare Conference Prepared Remarks Transcript

Relay Therapeutics, Inc. (RLAY) Presents at Wells Fargo 21st Annual Healthcare Conference Prepared Remarks Transcript

Seeking Alpha • Sep 10, 2026

Relay Therapeutics CFO Sells 17,717 Shares for $350,000

The sale had an approximate value of nearly $350,000. The transaction reduced the executive's direct equity position by 11%.

The Motley Fool • Sep 2, 2026

Relay Therapeutics to Participate in Two Upcoming Investor Conferences in September

CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, today announced that management will participate in two upcoming fireside chats in September:

GlobeNewsWire • Sep 1, 2026

This 'Dynamo' Biotech Puts AI-Fueled Breakout In Motion

After skyrocketing 1,027% off a low, Relay Therapeutics taps AI and machine learning to fuel more gains.

Investors Business Daily • Aug 20, 2026

4 AI-Powered Drug Discovery Stocks to Watch as AI Reshapes Pharma

RXRX, SDGR, RLAY and ABSI are using AI-powered platforms to transform drug discovery while advancing proprietary clinical pipelines.

Zacks Investment Research • Aug 17, 2026

Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates

Selected  z ovegalisib plus atirmociclib as go-forward triplet regimen for 1L breast cancer; Phase 3 1L trial in endocrine - sensitive patients expected to initiate in early 2027, subject to regulatory feedback

GlobeNewsWire • Aug 6, 2026

Relay Therapeutics, Inc. (RLAY) Reports Q2 Loss, Lags Revenue Estimates

Relay Therapeutics, Inc. (RLAY) came out with a quarterly loss of $0.41 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.41 per share a year ago.

Zacks Investment Research • Aug 7, 2026